DBV Technologies S.A. (DBVT): R&D Expense
$116.68M
Year ended 2025-12-31
+15.6%
3-year compound annual growth
+2.8%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $116.68M | +30.6% | 2026-03-26, From 2025-01-01 |
| 2024-12-31 | $89.34M | +48.4% | 2026-03-26, From 2024-01-01 |
| 2023-12-31 | $60.22M | -20.3% | 2025-04-11, From 2023-01-01 |
| 2022-12-31 | $75.54M | +7.4% | 2024-03-07, From 2022-01-01 |
| 2021-12-31 | $70.34M | -30.8% | 2023-03-02, From 2021-01-01 |
| 2020-12-31 | $101.61M | -11.7% | 2022-03-09, From 2020-01-01 |
| 2019-12-31 | $115.10M | n/a | 2021-03-17, From 2019-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $116.68M | +30.6% |
| Zeo ScientifiX, Inc. (ZEOX) | 2025-10-31 | $100.0K | -39.0% |
| Fate Therapeutics Inc (FATE) | 2025-12-31 | $107.83M | -20.1% |
| Prime Medicine, Inc. (PRME) | 2025-12-31 | $160.64M | +3.4% |
| Ocugen, Inc. (OCGN) | 2025-12-31 | $39.75M | +23.7% |
| CG Oncology, Inc. (CGON) | 2025-12-31 | $116.64M | +42.1% |
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | $284.81M | -8.2% |
| Surrozen, Inc. (SRZN) | 2025-12-31 | $29.36M | +39.0% |
| Curis Inc (CRIS) | 2025-12-31 | $28.25M | -26.7% |
Compare DBVT, ZEOX, FATE, PRME side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗